Graph Therapeutics, a next-generation techbio company developing precision medicines
for inflammatory and immune-mediated diseases, has secured a new $5 million
investment led by Daphni, the Paris-based venture capital firm. Daphni joins
Graph’s existing investor syndicate, which includes SquareOne, Merantix
Capital, and NAVEC Investment Management. The company has also secured
additional non-dilutive funding from the Austrian Research Promotion Agency
(FFG) and Austria Wirtschaftsservice (AWS).
With this latest
financing, Graph has raised more than $10 million to date, including equity
investments and non-dilutive grant funding.
Graph combines
perturbation modelling of complex live patient samples, functional and
multi-omics profiling, and advanced machine learning through its proprietary
“lab-in-the-loop” AI platform to decode immune dysfunction at scale.
By generating insights directly from real patient tissue, the company
identifies disease mechanisms, novel therapeutic targets, and biomarkers that
inform the development of differentiated therapies.
Building on a
platform that has been substantially validated and de-risked, Graph is
advancing an internal pipeline of precision therapeutics targeting complex
inflammatory and immune-mediated diseases.
The company has
significantly de-risked and validated its platform through clinically relevant
biological models, creating a strong foundation for the development of novel
therapeutic programs. The maturity of the platform also opens opportunities for
strategic partnerships and out-licensing initiatives, extending the impact of
Graph’s technology beyond its internal pipeline.
The new capital
will support the advancement of Graph’s internal drug discovery pipeline across
multiple inflammatory and immune-mediated disease indications, while further
expanding the company’s platform capabilities and strategic partnership
opportunities.